(0.19%) 5 141.50 points
(0.16%) 38 502 points
(0.26%) 17 893 points
(-0.32%) $83.58
(1.98%) $1.961
(0.13%) $2 350.30
(0.50%) $27.67
(1.15%) $932.75
(-0.04%) $0.934
(-0.13%) $11.01
(-0.16%) $0.799
(1.58%) $93.33
@ $45.15
发出时间: 15 Feb 2024 @ 04:24
回报率: -12.20%
上一信号: Feb 15 - 00:15
上一信号:
回报率: -2.59 %
Live Chart Being Loaded With Signals
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs...
Stats | |
---|---|
今日成交量 | 534 220 |
平均成交量 | 1.15M |
市值 | 2.65B |
EPS | $0 ( 2024-02-13 ) |
下一个收益日期 | ( $0.470 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -264.27 |
ATR14 | $0.0230 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Buechler Kenneth F | Buy | 9 041 | Common Stock |
2024-04-12 | Buechler Kenneth F | Sell | 9 041 | Non-Qualified Stock Option |
2024-03-28 | Iskra Michael S. | Buy | 4 925 | Common Stock |
2024-03-28 | Iskra Michael S. | Sell | 1 773 | Common Stock |
2024-03-28 | Iskra Michael S. | Sell | 4 925 | Restricted Stock Units |
INSIDER POWER |
---|
45.41 |
Last 100 transactions |
Buy: 322 615 | Sell: 120 021 |
音量 相关性
Quidel Corp 相关性 - 货币/商品
Quidel Corp 财务报表
Annual | 2023 |
营收: | $2.99B |
毛利润: | $1.28B (42.87 %) |
EPS: | $-0.150 |
FY | 2023 |
营收: | $2.99B |
毛利润: | $1.28B (42.87 %) |
EPS: | $-0.150 |
FY | 2022 |
营收: | $3.27B |
毛利润: | $1.94B (59.28 %) |
EPS: | $9.66 |
FY | 2021 |
营收: | $1.70B |
毛利润: | $1.27B (74.82 %) |
EPS: | $16.74 |
Financial Reports:
No articles found.
Quidel Corp
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。